The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a greater substantial decrease in body size and improve metabolic function, par